Introduction
============

Cystic fibrosis (CF) is the most common severe inherited monogenic disease in Caucasians, with an incidence of 1: 2500. Besides the F508del mutation, which accounts for the majority of CF alleles, almost 2000 different rare mutations have been described in the *CFTR* gene. Although no more than 20 of them occur at a frequency higher than 0.1% worldwide ([@b1-jomb-2014-0055]), the geographical heterogeneity of CF causing alleles demands the use of population specific mutation detection panels in order to reach reasonably high mutation detection rates.

Here, we present the mutational spectrum of CF patients in a Hungarian cohort which supplements the results of our previous study from Eastern Hungary ([@b2-jomb-2014-0055]).

Materials and Methods
=====================

Altogether 45 CF patients (22 males and 23 females, 10.1±8.1 years) were involved in this study. Sample collection and analysis were performed between 2010 and 2014. We selected patients with a clinical picture of classical CF, where both disease-causing mutations were identified. All patient samples were sent by Hungarian care centers (mainly from the regions of Budapest, Szeged and Debrecen). DNA was isolated from peripheral blood leukocytes with the QIAgen Blood Mini Kit (Qiagen, Hilden, Germany).

The first line molecular test -- if it had not been carried out by another laboratory before -- was a commercially available multiplex allele specific PCR assay, which is able to detect 29 mutations and differentiates between hetero- or homozygous forms of F508del (Elucigene™ CF29 v.2 kit, Tepnel Diagnostics Ltd, Abingdon, UK). Any mutation found other than F508del was further examined by sequence analysis of the corresponding region in order to determine if one or both alleles were affected. The first tier assay was complemented by an allele specific PCR to detect the common »Slavic« deletion, CFTRdele2,3(21kb) ([@b3-jomb-2014-0055]). As a second tier mutation analysis Sanger sequencing of the entire coding region was employed as described before ([@b2-jomb-2014-0055]) to find small-scale mutations elusive of the commercial assay. According to our previous experience ([@b2-jomb-2014-0055]), we started sequencing of exons 4, 6, 11, 14, 15 and 20, containing prevalent Hungarian mutations such as 2184insA (c.2052_2053insA), L101X (c.302T\>G) and Y1092X (c.3276C\>A); if no alteration was detected, the remaining exons were also tested. As a third tier step, MLPA analysis was used to detect large-scale rearrangements (SALSA MLPA KIT P091-B1 CFTR, MRC-Holland, Amsterdam, the Netherlands). If the sending institution had already performed first-line testing, we carried out only the second and/or third level of molecular analysis.

One gross rearrangement in the *CFTR* gene (CFTRdele2, c.54-5811_164+2186del273+6780_273+6961inv) which was detected by MLPA analysis was confirmed by allele specific PCR and bidirectional sequencing of the junction regions, as described in the literature ([@b7-jomb-2014-0055]--[@b9-jomb-2014-0055]).

The numbering of *CFTR* exons was done according to the current recommendations (Ensembl ENSG00000001626). In the mutation nomenclature both the legacy names and cDNA based HGVS names were used as proposed ([@b4-jomb-2014-0055]).

Results
=======

[Table I](#tI-jomb-2014-0055){ref-type="table"} shows the distribution of detected mutations in our recent study compared to Czech ([@b5-jomb-2014-0055]), Polish ([@b6-jomb-2014-0055]) and previous Hungarian ([@b2-jomb-2014-0055]) papers. Altogether 27 different mutations were found. F508del was detected in 53.3%, four mutations (W1282X, N1303K, CFTRdele2,3(21 kb), and 2184insA) were detected in 4.4% of alleles, while another four mutations (G542X, Y1092X, 621+ 1G\>T, and 2143delT) were found in more than one allele.

As shown in [Table II](#tII-jomb-2014-0055){ref-type="table"}, the commercially available assay was able to detect 75.9% of the mutations in our combined mutational database. The allele specific PCR for CFTRdele2,3(21kb) revealed 4.7% of disease-causing alleles. By the sequencing of exon 14 2184insA and two other rare mutations (c.2012delT and c.2002C\>T) were found with a frequency of 4.7%, 1.2% and 0.6%, respectively. The remaining mutations were scattered throughout the entire coding region of the *CFTR* gene. MLPA analysis revealed one deletion affecting exon 2 in one patient in a heterozygous form. Allele specific PCR and sequencing analysis showed that the single exon deletion detected by MLPA was the same as previously described by others ([@b10-jomb-2014-0055], [@b11-jomb-2014-0055]).

Discussion
==========

We updated our existing CF database by merging recently acquired nationwide results with our previous data from Eastern Hungary ([@b2-jomb-2014-0055]). Allele frequencies and proportion of detected mutations at different levels are listed in [Table II](#tII-jomb-2014-0055){ref-type="table"}. Data of our combined database are discussed below.

Altogether, 31 different mutations were identified in our previous and recent studies, two of which were novel (according to the Clinical and Functional Translation of CFTR database, cftr2.org and the Human Gene Mutation Database (HGMD)). These newly described sequence alterations are most likely pathogenic. One of them changes the reading frame, generating a premature stop codon 17 amino acids downstream (c.1037_1038insA, p.Leu346Hisfs\*17). Pathogenicity of the detected novel missense mutation c.1394C\>T, p.Thr465Ile is supported by the following: 1) the affected residue is located at a phylogenetically highly conserved position according to the orthologs of *Bos taurus, Equus caballus, Felis catus, Mus musculus* etc.; 2) another pathogenic mutation (T465N) affecting the same amino acid residue has already been described ([@b12-jomb-2014-0055]); 3) SIFT analysis predicts a damaging effect on the protein function.

Eleven mutations reached a frequency higher than 1%. In accordance with the literature ([@b5-jomb-2014-0055], [@b6-jomb-2014-0055]), the decreasing »North-to-South« gradient ([@b13-jomb-2014-0055]) stands for the distribution of F508del (104/170 CF alleles) compared to the Czech Republic, but not to Poland. F508del was followed by the Mediterranean mutation N1303K, the »Slavic« mutation CFTRdele2,3(21kb) and the »Galican« mutation 2184insA, each responsible for 4.7% of all CF alleles, which meets our previous observations. G542X was detected in 2.9%, the Israeli mutation W1282X in 2.4%. Other relatively frequent mutations were Y1092X, L101X found in 1.8% and 621+1G\>T, S466X, 2143delT found in 1.2% of the patients. One gross rearrangement (0.6%) in the *CFTR* gene (CFTRdele2, c.54-5811_164+2186del273+6780_273+6961inv) was detected by MLPA analysis and confirmed by allele specific PCR and bidirectional sequencing of the junction regions, as described in the literature ([@b7-jomb-2014-0055]). The mutation is characterized by a deletion of 8108bp (part of intron 1, the whole exon 2 and part of intron 2) with an inverted insertion of 182 bp from intron 3 ([@b11-jomb-2014-0055]).

As demonstrated in [Figure 1](#f1-jomb-2014-0055){ref-type="fig"}, geographical tendencies can be recognized in the distribution of both CFTRdele2,3(21kb) and 2184insA mutations. All but one CFTRdele2,3(21kb) and 2184insA positive samples originate from the northern regions of the country and 2184insA even seems to be restricted to the northeastern territories of Hungary, which is not suprising if we consider the high frequency of this mutation in Western Ukraine ([@b14-jomb-2014-0055]).

According to the mapped mutation frequencies in patients originating from different regions of Hungary using the commercially available assay 75.9% of the mutations can be identified. The allele specific PCR for the detection of the common »Slavic« deletion, CFTRdele2,3(21kb) adds 4.7%, while the sequencing of exon 14 adds 6.5% to the proportion of detected mutations. MLPA analysis revealed one rearrangement (0.6%), while direct sequencing of the entire coding region of *CFTR* gene identified 20 CF alleles (11.8%).

However, it should be noted that the detection of CFTRdele2,3(21kb) would have been possible by MLPA as well.

In conclusion, beside determining mutation distribution in Hungarian CF patients, our study provides a good starting point to the genetic testing following newborn screening. The commercial allele specific mutation detection method detects 75.9% of *CFTR* mutations. Complementing it with the detection of other two frequent population-specific alterations (i.e. CFTRdele2,3(21kb) and 2184insA) \~85% of mutations can be detected to achieve the required sensitivity (85--90%) in newborn screening (15 and Milan Macek, personal communication).

With the growing popularity of the clinical use of next generation sequencing (NGS) methods, one possible solution of the combined (i.e. all tiers) DNA analysis step of NBS programs would be the use of those tests.

However, based on our results, it also has to be emphasized that using NGS methods with a high error rate in homopolymer regions (e.g. pyrosequencing or ion semiconductor sequencing) in genetic testing will fail to detect \~5% of CF alleles (2184insA mutation). The frequent »Slavic« mutation (\~5%) would be missed as well unless applying a very high coverage not usual in germline mutation detection or using commercially available kits including this mutation, but both of these solutions raise unnecessary financial burdens.
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###### 

Mutation distribution in our patient cohort compared to Czech ([@b5-jomb-2014-0055]), Polish ([@b6-jomb-2014-0055]) and previous Hungarian ([@b2-jomb-2014-0055]) publications.

  HGVS nomenclature                           Legacy name/effect on protein level   Hungary 2011 (N=80)   Czech Republic 2013 (N=1200)   Poland 2014 (N=1476)   This study (N=90)
  ------------------------------------------- ------------------------------------- --------------------- ------------------------------ ---------------------- -------------------
  c.1521_1523delCTT                           F508del                               70.0%                 67.4%                          54.5%                  53.3%
  c.3846G\>A                                  W1282X                                0.0%                  0.6%                           0.6%                   4.4%
  c.3909C\>G                                  N1303K                                5.0%                  2.4%                           1.2%                   4.4%
  c.54-5940_273+10250del21kb                  CFTRdele2,3(21kb)                     5.0%                  5.8%                           4.5%                   4.4%
  c.2052_2053insA                             2184insA                              5.0%                  0.4%                           1.0%                   4.4%
  c.1624G\>T                                  G542X                                 3.8%                  2.0%                           1.7%                   2.2%
  c.489+1G\>T                                 621+1G\>T                             0.0%                  0.4%                           0.3%                   2.2%
  c.3276C\>A                                  Y1092X                                1.3%                  0.0%                           0.1%                   2.2%
  c.302T\>G                                   L101X                                 2.5%                  0.0%                           0.1%                   1.1%
  c.1397C\>G                                  S466X                                 1.3%                  0.0%                           0.1%                   1.1%
  c.2012delT                                  2143delT                              0.0%                  0.9%                           1.8%                   2.2%
  c.53+1G\>T                                  185+1G\>T                             0.0%                  0.2%                           0.0%                   1.1%
  c.1394C\>T                                  p.Thr465Ile                           0.0%                  0.0%                           0.0%                   1.1%
  c.1037_1038insA                             p.Leu346Hisfs\*17                     0.0%                  0.0%                           0.0%                   1.1%
  c.2051_2052delAAinsG                        2183AA\>G                             0.0%                  0.1%                           0.7%                   1.1%
  c.2657+5G\>A                                2789+5G\>A                            0.0%                  0.5%                           0.0%                   1.1%
  c.3717+12191C\>T                            3849+10kbC\>T                         0.0%                  1.7%                           3.9%                   1.1%
  c.215C\>A                                   A72D                                  0.0%                  0.0%                           0.0%                   1.1%
  c.3454G\>C                                  D1152H                                0.0%                  0.0%                           0.1%                   1.1%
  c.3731G\>A                                  G1244E                                0.0%                  0.0%                           0.0%                   1.1%
  c.1727G\>C                                  G576A                                 0.0%                  0.0%                           0.3%                   1.1%
  c.3302T\>A                                  M1101K                                0.0%                  0.0%                           0.0%                   1.1%
  c.2591_2592delTT                            2723delTT                             0.0%                  0.0%                           0.0%                   1.1%
  c.3822G\>A                                  W1274X                                0.0%                  0.0%                           0.0%                   1.1%
  c.2002C\>T                                  R668C                                 0.0%                  0.0%                           0.2%                   1.1%
  c.325_327delTATinsG                         p.Tyr109Glyfs\*4                      0.0%                  0.0%                           0.0%                   1.1%
  c.54-5811_164+2186del273+6780_273+6961inv   CFTRdele2                             0.0%                  0.2%                           0.0%                   1.1%

###### 

Allele frequencies and mutation detection rates in the combined mutational database. Novel mutations are in bold.

  Exon/intron   HGVS nomenclature                            Legacy name/effect on protein level   No. of alleles (N=170)   Frequency of alleles   Mutation in trans          Proportion of detected mutations
  ------------- -------------------------------------------- ------------------------------------- ------------------------ ---------------------- -------------------------- ----------------------------------------------
  e11           c.1521_1523delCTT                            F508del                               104                      61.2%                  various CF mutations       Elucigene CF29v.2 75.9%
  e23           c.3846G\>A                                   W1282X                                4                        2.4%                   F508del, 2184insA, W1282   
  e24           c.3909C\>G                                   N1303K                                8                        4.7%                   various CF mutations       
  e12           c.1624G\>T                                   G542X                                 5                        2.9%                   various CF mutations       
  i11           c.1585-1G\>A                                 1717-1G\>A                            1                        0.6%                   F508del                    
  e8            c.1040G\>C                                   R347P                                 1                        0.6%                   G542X                      
  e14           c.2051_2052delAAinsG                         2183AA\>G                             1                        0.6%                   D1152H                     
  i16           c.2657+5G\>A                                 2789+5G\>A                            1                        0.6%                   621+1G\>T                  
  i4            c.489+1G\>T                                  621+1G\>T                             2                        1.2%                   F508del, 2789+5G\>A        
  e21           c.3454G\>C                                   D1152H                                1                        0.6%                   2183AA\>G                  
  i22           c.3717+12191C\>T                             3849+10kbC\>T                         1                        0.6%                   F508del                    
  i1-i3         c.54-5940_273+ 10250del21kb                  CFTRdele2,3(21kb)                     8                        4.7%                   F508del, N1303K, Y109G     "Slavic PCR" 4.7%
  e14           c.2052_2053insA                              2184insA                              8                        4.7%                   F508del, G542X, W1282      Sequencing of e14 6.5%
  e14           c.2012delT                                   2143delT                              2                        1.2%                   F508del                    
  e14           c.2002C\>T                                   R668C                                 1                        0.6%                   G576A                      
  e20           c.3276C\>A                                   Y1092X                                3                        1.8%                   F508del                    Sequencing of the entire coding region 11.8%
  e4            c.302T\>G                                    L101X                                 3                        1.8%                   F508del, 2723delTT         
  e11           c.1397C\>G                                   S466X                                 2                        1.2%                   F508del                    
  i1            c.53+1G\>T                                   185+1G\>T                             1                        0.6%                   N1303K                     
  e11           **c.1394C\>T**                               **p.Thr465Ile**                       1                        0.6%                   F508del                    
  e8            **c.1037_1038insA**                          **p.Leu346Hisfs\*17**                 1                        0.6%                   F508del                    
  e3            c.215C\>A                                    A72D                                  1                        0.6%                   N1303K                     
  e15           c.2491G\>T                                   E831X                                 1                        0.6%                   N1303K                     
  e6            c.658C\>T                                    Q220X                                 1                        0.6%                   F508del                    
  e23           c.3731G\>A                                   G1244E                                1                        0.6%                   F508del                    
  e13           c.1727G\>C                                   G576A                                 1                        0.6%                   R668C                      
  e20           c.3302T\>A                                   M1101K                                1                        0.6%                   F508del                    
  e15           c.2591_2592delTT                             2723delTT                             1                        0.6%                   L101X                      
  e23           c.3822G\>A                                   W1274X                                1                        0.6%                   F508del                    
  e4            c.325_327delTATinsG                          p.Tyr109Glyfs\*4                      1                        0.6%                   CFTRdele2,3(21kb)          
  i1-i2         c.54-5811_164+2186del273 +6780_273+6961inv   CFTRdele2                             1                        0.6%                   F508del                    MLPA 0.6%
